Peripheral Blood Complement Factors C2 and C3 As Biomarkers of Clinical Efficacy in Patients with First-episode Schizophrenia After Aripiprazole Treatment

Overview

Journal BMC Psychiatry

Publisher Biomed Central

Specialty Psychiatry

Date 2024 Dec 31

PMID 39741241

Authors

Yin Cao

Jun Liang

Biao Dai

Feng Shan

Qingrong Xia

Affiliations

Soon will be listed here.

Abstract

Objective: The objective of this study was to identify serum complement factor-based biomarkers indicative of clinical efficacy in patients with first-episode schizophrenia (SCZ) following treatment with aripiprazole.

Methods: The retrospective study cohort comprised 40 patients diagnosed with first-episode SCZ (SCZ group) and 40 healthy individuals (control group). Quantitative analyses were conducted on five complement factors, namely complement component 1 (C1), C2, C3, C4, and the 50% hemolytic complement (CH50). Baseline serum complement factor levels were compared between the SCZ and control groups. Patients diagnosed with SCZ underwent a 4-week treatment regimen with aripiprazole. The severity of psychiatric symptoms in these patients was assessed using the Positive and Negative Symptom Scale (PANSS) and the Brief Psychiatric Rating Scale-18 Item Version (BPRS). Comparative analyses were conducted on PANSS and BPRS scores, as well as serum complement factor levels, both prior to (pre-treatment group) and following aripiprazole administration (post-treatment group). Pearson's correlation test was employed to evaluate the relationships between changes in serum complement factor levels and the reduction rates of PANSS/BPRS scores.

Results: At baseline, patients with SCZ exhibited significantly elevated levels of C1, C2, C3, C4, and CH50 compared to the control group (P < 0.05). Moreover, following treatment, there was a significant reduction in the PANSS total score, positive symptom score, negative symptom score, and BPRS score in the post-treatment group compared to the pre-treatment group (P < 0.05). Furthermore, patients in the post-treatment group exhibited a significant reduction in serum levels of C2, C3, and C4, alongside a significant increase in the serum level of CH50 compared to those in the pre-treatment group (P < 0.05). Additionally, the baseline serum C2 levels and the variations in serum C2 levels pre- and post-treatment exhibited a negative correlation with the reduction rate of PANSS/BPRS scores (P < 0.05). Similarly, both the baseline serum C3 levels and the changes in serum C3 levels pre- and post-treatment were negatively correlated with the reduction rate of PANSS/BPRS scores (P < 0.05).

Conclusion: Baseline serum levels of C2 and C3, as well as their variations pre- and post-treatment, may serve as biomarkers for predicting clinical efficacy in patients with first-episode SCZ undergoing treatment with aripiprazole.

References

Magdalon J, Mansur F, Teles E Silva A, de Goes V, Reiner O, Sertie A . Complement System in Brain Architecture and Neurodevelopmental Disorders. Front Neurosci. 2020; 14:23. PMC: 7015047. DOI: 10.3389/fnins.2020.00023. View

Nucifora Jr F, Woznica E, Lee B, Cascella N, Sawa A . Treatment resistant schizophrenia: Clinical, biological, and therapeutic perspectives. Neurobiol Dis. 2018; 131:104257. PMC: 6395548. DOI: 10.1016/j.nbd.2018.08.016. View

Vergani E, Bruno C, Napodano C, Gulli F, Stefanile A, Piunno G . Immune dyscrasia in adult growth hormone deficiency: Evaluation of hemolytic complement activity (CH50) and IgG subclasses. Biomed Pharmacother. 2020; 131:110757. DOI: 10.1016/j.biopha.2020.110757. View

Zhang Z, Deng H, Chen Y, Li S, Zhou Q, Lai H . Cross-sectional survey of the relationship of symptomatology, disability and family burden among patients with schizophrenia in Sichuan, China. Shanghai Arch Psychiatry. 2014; 26(1):22-9. PMC: 4117999. DOI: 10.3969/j.issn.1002-0829.2014.01.004. View

Sobis J, Rykaczewska-Czerwinska M, Swietochowska E, Gorczyca P . Therapeutic effect of aripiprazole in chronic schizophrenia is accompanied by anti-inflammatory activity. Pharmacol Rep. 2015; 67(2):353-9. DOI: 10.1016/j.pharep.2014.09.007. View

Kay S, Fiszbein A, Opler L . The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull. 1987; 13(2):261-76. DOI: 10.1093/schbul/13.2.261. View

Khandaker G, Cousins L, Deakin J, Lennox B, Yolken R, Jones P . Inflammation and immunity in schizophrenia: implications for pathophysiology and treatment. Lancet Psychiatry. 2015; 2(3):258-270. PMC: 4595998. DOI: 10.1016/S2215-0366(14)00122-9. View

Pouw R, Ricklin D . Tipping the balance: intricate roles of the complement system in disease and therapy. Semin Immunopathol. 2021; 43(6):757-771. PMC: 8547127. DOI: 10.1007/s00281-021-00892-7. View

Raskin A . Discussion: recent developments in ascertainment and scaling of the BPRS. Psychopharmacol Bull. 1988; 24(1):122-4. View

10.

Hamlyn J, Duhig M, McGrath J, Scott J . Modifiable risk factors for schizophrenia and autism--shared risk factors impacting on brain development. Neurobiol Dis. 2012; 53:3-9. DOI: 10.1016/j.nbd.2012.10.023. View

11.

Nimgaonkar V, Yolken R . Neurotropic infectious agents and cognitive impairment in schizophrenia. Schizophr Bull. 2012; 38(6):1135-6. PMC: 3494054. DOI: 10.1093/schbul/sbs125. View

12.

Chen Y, Zhao Z, Lin F, Wang L, Lin Z, Yue W . Associations Between Genotype and Peripheral Complement Proteins in First-Episode Psychosis: Evidences From C3 and C4. Front Genet. 2021; 12:647246. PMC: 8301372. DOI: 10.3389/fgene.2021.647246. View

13.

Tange C, Johnson-Brett B, Cook A, Stordeur P, Brohet F, Jolles S . Quantification of human complement C2 protein using an automated turbidimetric immunoassay. Clin Chem Lab Med. 2018; 56(9):1498-1506. DOI: 10.1515/cclm-2017-1068. View

14.

Agid O, Kapur S, Arenovich T, Zipursky R . Delayed-onset hypothesis of antipsychotic action: a hypothesis tested and rejected. Arch Gen Psychiatry. 2003; 60(12):1228-35. DOI: 10.1001/archpsyc.60.12.1228. View

15.

Su J, Feng X, Chen K, Fang Z, Zhang H . Plasma complement component 4 alterations in patients with schizophrenia before and after antipsychotic treatment. Asian J Psychiatr. 2022; 73:103110. DOI: 10.1016/j.ajp.2022.103110. View

16.

Dalakas M, Alexopoulos H, Spaeth P . Complement in neurological disorders and emerging complement-targeted therapeutics. Nat Rev Neurol. 2020; 16(11):601-617. PMC: 7528717. DOI: 10.1038/s41582-020-0400-0. View

17.

Gosek P, Kotowska J, Rowinska-Garbien E, Bartczak D, Heitzman J . Treatment resistance and prolonged length of stay among schizophrenia inpatients in forensic institutions. Psychiatry Res. 2021; 298:113771. DOI: 10.1016/j.psychres.2021.113771. View

18.

Alvarez-Herrera S, Escamilla R, Medina-Contreras O, Saracco R, Flores Y, Hurtado-Alvarado G . Immunoendocrine Peripheral Effects Induced by Atypical Antipsychotics. Front Endocrinol (Lausanne). 2020; 11:195. PMC: 7186385. DOI: 10.3389/fendo.2020.00195. View

19.

Tanskanen A, Taipale H, Cannon M, Cotter D, Tiihonen J . Incidence of schizophrenia and influence of prenatal and infant exposure to viral infectious diseases. Acta Psychiatr Scand. 2021; 143(6):487-494. DOI: 10.1111/acps.13295. View

20.

Preda A, Shapiro B . A safety evaluation of aripiprazole in the treatment of schizophrenia. Expert Opin Drug Saf. 2020; 19(12):1529-1538. DOI: 10.1080/14740338.2020.1832990. View